@doorparade7
Active 10 months, 2 weeks ago
The 12-week ARM-TD and AIM-TD studies in tardive dyskinesia (TD) patients showed statistically significant improvements in TD symptoms with deutetrabenazine. The completed open-label extension (OLE) study (SD-809-C-20) evaluated long-term efficacy and safety of deutetrabenazine in TD.
Patients who completed ARM-TD or AIM-TD enrolled in […] View